1st Department of Cardiology, Athens Medical School, Hippokration Hospital, Athens, Greece.
Atherosclerosis. 2011 Jan;214(1):129-38. doi: 10.1016/j.atherosclerosis.2010.10.008. Epub 2010 Oct 15.
To evaluate the impact of familial hypercholesterolemia (FH) and familial combined hyperlipidemia (FCH) on arterial properties and the effects of statins.
We meta-analyzed 51 studies providing data for 4,057 FH patients and 732 FCH patients with random-effects models, meta-regression analysis and publication bias analysis. The main outcomes of interest were (1) brachial artery flow-mediated dilation (FMD), (2) intima-media thickness (IMT), and (3) change of IMT and FMD after treatment with statins.
Compared to normolipidemic controls, FH patients had lower FMD [pooled mean difference (MD): -5.31%, 95% CI -7.09 to -3.53%, P<0.001] and higher carotid IMT (pooled MD: 0.12mm, 95% CI 0.09-0.15mm, P<0.001) and femoral IMT (pooled MD: 0.35mm, 95% CI 0.18-0.51mm, P<0.001). FCH patients had lower FMD and increased IMT (pooled MD: -3.60%, 95% CI -6.69 to -0.50%, P=0.023; and 0.06mm, 95% CI 0.04-0.08mm, P<0.001, respectively). Total and LDL-cholesterol was a significant determinant of FMD and carotid IMT in FCH patients and of FMD and femoral IMT in FH patients. In FH patients, statins improved FMD (pooled MD of change: 5.39%, 95% CI 2.86-7.92%, P<0.001) and decreased carotid IMT (pooled MD of change: -0.025mm, 95% CI -0.042 to -0.009mm, P=0.003). Changes of both FMD and IMT with statins correlated with the duration×treatment intensity product in FH patients (both P<0.01). Additionally, statins improved FMD in FCH patients (pooled MD of change: 2.06%, 95% CI 0.43-3.69%, P=0.013). No significant publication bias was detected.
Arterial properties are impaired in subjects with FH or FCH. Statins improve arterial function and structure in FH patients in a treatment intensity-related manner.
评估家族性高胆固醇血症(FH)和家族性混合型高脂血症(FCH)对动脉功能的影响,以及他汀类药物的作用。
我们采用随机效应模型、荟萃回归分析和发表偏倚分析,对提供了 4057 例 FH 患者和 732 例 FCH 患者数据的 51 项研究进行了荟萃分析。主要观察指标为:(1)肱动脉血流介导的扩张(FMD),(2)内膜-中层厚度(IMT),(3)他汀类药物治疗后 IMT 和 FMD 的变化。
与血脂正常对照组相比,FH 患者的 FMD 较低[合并平均差异(MD):-5.31%,95%置信区间(CI):-7.09 至-3.53%,P<0.001],颈动脉 IMT(MD:0.12mm,95%CI:0.09-0.15mm,P<0.001)和股动脉 IMT(MD:0.35mm,95%CI:0.18-0.51mm,P<0.001)较高。FCH 患者的 FMD 较低,IMT 增加[MD:-3.60%,95%CI:-6.69 至-0.50%,P=0.023;MD:0.06mm,95%CI:0.04-0.08mm,P<0.001]。总胆固醇和 LDL 胆固醇是 FCH 患者 FMD 和颈动脉 IMT 以及 FH 患者 FMD 和股动脉 IMT 的显著决定因素。在 FH 患者中,他汀类药物改善了 FMD(MD 变化:5.39%,95%CI:2.86-7.92%,P<0.001)和颈动脉 IMT(MD 变化:-0.025mm,95%CI:-0.042 至-0.009mm,P=0.003)。FH 患者中,他汀类药物对 FMD 和 IMT 的改善与治疗时间×治疗强度的乘积呈正相关(均 P<0.01)。此外,他汀类药物还改善了 FCH 患者的 FMD(MD 变化:2.06%,95%CI:0.43-3.69%,P=0.013)。未发现明显的发表偏倚。
FH 或 FCH 患者的动脉功能受损。他汀类药物以治疗强度相关的方式改善 FH 患者的动脉功能和结构。